The Pharma Data

AUGUST 28, 2020

The government plans to train up an army of health professionals to be ready to give the coronavirus vaccine, if and when one is shown to work. The Department of Health and Social Care (DHSC) said this could include training a wider range of existing NHS staff, as well as student doctors and nurses. Image copyright. Getty Images.

Vaccine 52

Vaccine Immune Response Nurses Government 52

The Pharma Data

NOVEMBER 27, 2020

This week, another pharma company revealed a new technology device that can detect if a patient is infectious or not, while the Russian government published results of its Sputnik V vaccine, claiming it is more than 95 per cent efficient 42 days after the first dose. Read on to for the full insight.

Virus 52

Virus Vaccine International Immune Response 52

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., government, Regeneron is producing approximately 300,000 doses (2,400 mg) for outpatient use under the EUA. government regarding additional doses. . futility analysis). . In the U.S.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

DECEMBER 17, 2020

Nursing Mothers: There is currently no clinical experience in use of casirivimab and imdevimab injection in COVID-19 patients who are breastfeeding. Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load. As part of Operation Warp Speed, in July the U.S.

Therapies 52

Therapies FDA Clinical Trials Hospitals 52

The Pharma Data

NOVEMBER 21, 2020

government allocation program. The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

FDA 40

FDA Clinical Trials Hospitals Government 40

The Pharma Data

NOVEMBER 24, 2020

“These are immune responses, so if you feel something after vaccination, you should expect to feel that. She represents the National Association of Pediatric Nurse Practitioners, and said providers must be ready to explain this to people who line up to get any COVID-19 vaccine.

Vaccine 52

Vaccine Immune Response Virus Hospitals 52